Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 246

Epigenetic mechanisms (i.e., DNA methyltransferase and histone deacetylase [HDAC] inhibitors) might play a role in the loss of ER-alpha in ER-negative breast tumors. Preclinical studies have shown that pharmacologic inhibition of these mechanisms result in re-expression of functional ER mRNA and protein. The addition of an HDAC inhibitor, vorinostat, to endocrine therapy in the setting of endocrine-resistant disease appears to restore sensitivity in select patients, a hypothesis that is being carried forward in the setting of ER-negative breast cancer.

Figure 3 Invasive ductal carcinoma of breast on mammogram

Source: Medscape.